Completed PHASE3 INTERVENTIONAL NCT00000172

Evaluation of Galantamine in the Treatment of Alzheimer's Disease

Placebo Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy Under a Slow-Titration Regimen

Sponsor: Janssen, LP

Conditions Alzheimer Disease

Interventions Galantamine

Updated 6 times since 2017 Last updated: Jun 23, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Alzheimer Disease, this trial is completed. The trial is conducted by Janssen, LP and has accumulated 6 data snapshots since 2026. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Janssen, LP

Data source: National Institute on Aging (NIA)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Alexandria, United States , Baltimore, United States , Bennington, United States , Berkeley, United States , Birmingham, United States , Boston, United States , Centereach, United States , Chicago, United States , Colchester, United States and 40 more locations